01 October 2007
Liver lipid peroxidation in experimental Escherichia coli peritonitis: The role of myeloperoxidase and nitric oxide inhibition
Melek Demir, Ilknur Kaleli, Suleyman Demir, Selahattin Sert, Nural Cevahir, Umut Yildirim, Barbaros SahinMed Sci Monit 2007; 13(10): BR225-229 :: ID: 502344
Abstract
Background: The pathogenic mechanism of peritonitis is complex. The role of nitric oxide (NO) and myeloperoxidase (MPO) in liver lipid peroxidation accompanying bacterial peritonitis was evaluated.
Material/Methods: Peritonitis was induced by 0.2-ml intraperitoneal application of 10[sup]5[/sup] (low E. coli) or 2×10[sup]8[/sup] CFU/ml (high E. coli) E. coli isolated from a bacteriemic patient. A nonspecific nitric oxide synthase inhibitor, L-N[sup]G[/sup]-nitroarginine methyl ester (L-NAME, 8 mg/kg i.p.) was given to determine the potential involvement of nitric oxide. Female mice were divided into five groups: controls, low E. coli, low E. coli + L-NAME, high E. coli, and high E. coli + L-NAME. After 24 hours, peritoneal lavage fluids and hepatic tissue samples were obtained for microbiological and biochemical evaluation. Hepatic tissue malondialdehyde (MDA) levels were measured to determine the free radical-induced lipid peroxidation in peritonitis.
Results: MDA levels were increased in the high, but not in the low, E. coli group (p<0.001) compared with the controls. MDA levels were lower in the high E. coli + L-NAME group than in the high E. coli group, but still higher than in the control group (p<0.01). Liver myeloperoxidase (MPO) activities were increased in the high E. coli group (p<0.01), but not in the low E. coli group. L-NAME increased myeloperoxidase activities in both groups.
Conclusions: These results are consistent with the notion that NO and MPO contribute in liver tissue lipid peroxidation in peritonitis. NO may have different effects in hepatic damage depending on the severity of infection.
Keywords: Escherichia coli - physiology, Ascitic Fluid - microbiology, Lipid Peroxidation, Liver - microbiology, Malondialdehyde - metabolism, Nitric Oxide - metabolism, Peritonitis - microbiology, Peroxidase - metabolism
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
12 Mar 2024 : Clinical Research
Tissue Inhibitors of Metalloproteinase 1 (TIMP-1) and 3 (TIMP-3) as New Markers of Acute Kidney Injury Afte...Med Sci Monit In Press; DOI: 10.12659/MSM.943500
12 Mar 2024 : Review article
Optimizing Behçet Uveitis Management: A Review of Personalized Immunosuppressive StrategiesMed Sci Monit In Press; DOI: 10.12659/MSM.943240
12 Mar 2024 : Clinical Research
Metabolomic Alterations in Methotrexate Treatment of Moderate-to-Severe PsoriasisMed Sci Monit In Press; DOI: 10.12659/MSM.943360
14 Mar 2024 : Clinical Research
Renal Dysfunction Increases Risk of Adverse Cardiovascular Events in 5-Year Follow-Up Study of Intermediate...Med Sci Monit In Press; DOI: 10.12659/MSM.943956
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952